Introduction
Application of lipid nanoparticles in lung cancer treatment
Study title | Condition (regarding lung cancer) | Study phase | Status | Identifier |
---|---|---|---|---|
A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors | Advanced solid tumors | 1 | Recruiting | NCT05267899 |
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies | Relapsed/Refractory solid tumor malignancies | 1 | Recruiting | NCT03739931 |
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies | Relapsed/Refractory solid tumor malignancies | 1 | Terminated | NCT03323398 |
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | Solid tumors | 1 | Terminated | NCT02110563 |
Reqorsa (Quaratusugene Ozeplasmid) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer (Acclaim-2) | Non-small-cell lung cancer | 1/2 | Recruiting | NCT05062980 |
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1) | Carcinoma, non-small-cell lung cancer | 1/2 | Recruiting | NCT04486833 |
First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors | Solid tumor | 1 | Recruiting | NCT04675996 |
A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I) | Solid tumor | 1/2 | Recruiting | NCT05497453 |
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3) | Small-cell lung cancer Extensive Stage | 1/2 | Not yet recruiting | NCT05703971 |